Kass ME. Pathology of peritoneal mesothelioma. Cancer Treat Res. 1996;81:213–25.

Article  CAS  PubMed  Google Scholar 

Baratti D, Kusamura S, Nonaka D, Oliva GD, Laterza B, Deraco M. Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC). Ann Surg Oncol. 2007;14(10):2790–7.

Article  CAS  PubMed  Google Scholar 

Churg A, Allen T, Borczuk AC, Cagle PT, Galateau-Sallé F, Hwang H, et al. Well-differentiated papillary mesothelioma with invasive foci. Am J Surg Pathol. 2014;38(7):990–8.

Article  PubMed  Google Scholar 

Zhang CH, Yu JW, Luo M. Multicystic peritoneal mesothelioma: a short review. Curr Probl Cancer. 2017;41(5):340–8.

Article  PubMed  Google Scholar 

Boffetta P. Epidemiology of peritoneal mesothelioma: a review. Ann Oncol. 2007;18(6):985–90.

Article  CAS  PubMed  Google Scholar 

Kusamura S, Kepenekian V, Villeneuve L, Lurvink RJ, Govaerts K, De Hingh I, et al. Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol. 2021;47(1):36–59.

Article  CAS  PubMed  Google Scholar 

Calthorpe L, Romero-Hernandez F, Casey M, Nunez M, Conroy PC, Hirose K, et al. National practice patterns in malignant peritoneal mesothelioma: updates in management and survival. Ann Surg Oncol. 2023;30(8):5119–29.

Article  PubMed  Google Scholar 

Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27(36):6237–42.

Article  PubMed  Google Scholar 

Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–74.

Article  CAS  PubMed  Google Scholar 

Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.

Article  PubMed  PubMed Central  Google Scholar 

Sugarbaker PH, Yan TD, Stuart OA, Yoo D. Comprehensive management of diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol. 2006;32(6):686–91.

Article  CAS  PubMed  Google Scholar 

Yano H, Moran BJ, Cecil TD, Murphy EM. Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal mesothelioma. Eur J Surg Oncol. 2009;35(9):980–5.

Article  CAS  PubMed  Google Scholar 

Feldman AL, Libutti SK, Pingpank JF, Bartlett DL, Beresnev TH, Mavroukakis SM, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003;21(24):4560–7.

Article  CAS  PubMed  Google Scholar 

Kyang LS, Alzahrani NA, Valle SJ, Rahman MK, Arrowaili A, Liauw W, et al. Long-term survival outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy: single-institutional experience with 1225 cases. J Surg Oncol. 2019;120(4):794–802.

Article  PubMed  Google Scholar 

Valenzuela CD, Solsky IB, Erali RA, Forsythe SD, Mangieri CW, Mainali BB, et al. Long-term survival in patients treated with cytoreduction and heated Intraperitoneal chemotherapy for peritoneal mesothelioma at a single high-volume center. Ann Surg Oncol. 2023;30(5):2666–75.

Article  PubMed  PubMed Central  Google Scholar 

Kusamura S, Torres Mesa PA, Cabras A, Baratti D, Deraco M. The role of Ki-67 and pre-cytoreduction parameters in selecting diffuse malignant peritoneal mesothelioma (DMPM) patients for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2016;23(5):1468–73.

Article  PubMed  Google Scholar 

Magge D, Zenati MS, Austin F, Mavanur A, Sathaiah M, Ramalingam L, et al. Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Ann Surg Oncol. 2014;21(4):1159–65.

Article  PubMed  Google Scholar 

Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636–44.

Article  CAS  PubMed  Google Scholar 

Fujimoto E, Kijima T, Kuribayashi K, Negi Y, Kanemura S, Mikami K, et al. First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma. Expert Rev Anticancer Ther. 2017;17(9):865–72.

Article  CAS  PubMed  Google Scholar 

Jänne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, et al. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer. 2005;7(1):40–6.

Article  PubMed  Google Scholar 

Carteni G, Manegold C, Garcia GM, Siena S, Zielinski CC, Amadori D, et al. Malignant peritoneal mesothelioma-results from the international expanded access program using pemetrexed alone or in combination with a platinum agent. Cancer Treat Res. 2009;64(2):211–8.

CAS  Google Scholar 

Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (checkMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375–86.

Article  CAS  PubMed  Google Scholar 

Raghav K, Liu S, Overman M, Morani A, Willette A, Fournier K, et al. Clinical efficacy of immune checkpoint inhibitors in patients with advanced malignant peritoneal mesothelioma. JAMA Netw Open. 2021;4(8):e2119934.

Article  PubMed  PubMed Central  Google Scholar 

Raghav K, Liu S, Overman MJ, Willett AF, Knafl M, Fu SC, et al. Efficacy, safety, and biomarker analysis of combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) blockade in advanced malignant peritoneal mesothelioma. Cancer Discov. 2021;11(11):2738–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marmarelis ME, Wang X, Roshkovan L, Walker S, McNulty S, Ciunci CA, et al. Real-world outcomes of pembrolizumab in peritoneal mesothelioma. JCO. 2020;38(15):e21094–e21094.

Article  Google Scholar 

Ettinger DS, Wood DE, Stevenson J, Aisner DL, Akerley W, Bauman JR, et al. Mesothelioma: peritoneal, version 2.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023;21(9):961–79.

Article  CAS  PubMed  Google Scholar 

Le Roy F, Gelli M, Hollebecque A, Honoré C, Boige V, Dartigues P, et al. Conversion to complete cytoreductive surgery and hyperthermic Intraperitoneal chemotherapy for malignant peritoneal mesothelioma after bidirectional chemotherapy. Ann Surg Oncol. 2017;24(12):3640–6.

Article  PubMed  Google Scholar 

Sugarbaker PH, Chang D. Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival. Eur J Surg Oncol. 2017;43(7):1228–35.

Article  CAS  PubMed  Google Scholar 

Giger-Pabst U, Demtröder C, Falkenstein TA, Ouaissi M, Götze TO, Rezniczek GA, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for the treatment of malignant mesothelioma. BMC Cancer. 2018;18(1):442.

Article  PubMed  PubMed Central  Google Scholar 

Kepenekian V, Péron J, You B, Bonnefoy I, Villeneuve L, Alyami M, et al. Non-resectable malignant peritoneal mesothelioma treated with pressurized Intraperitoneal aerosol chemotherapy (PIPAC) plus systemic chemotherapy could lead to secondary complete cytoreductive surgery: a cohort study. Ann Surg Oncol. 2022;29(3):2104–13.

Article  PubMed  Google Scholar 

Chua TC, Yan TD, Deraco M, Glehen O, Moran BJ, Sugarbaker PH. Multi-institutional experience of diffuse intra-abdominal multicystic peritoneal mesothelioma. Br J Surg. 2011;98(1):60–4.

Article  CAS  PubMed  Google Scholar